Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG106 + PD-1 Antibody in Advanced Solid Tumors and NHL
NCT04775680Phase 2Terminated
- Sponsor
- Adagene
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ADG106 in solid tumor, non-Hodgkin lymphoma (NHL), sponsored by Adagene. Started Mar 2021; status: terminated.
02
Drugs
ADG106
03
Conditions
solid tumornon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT04775680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04775680.